Found 223 clinical trials
Multicenter Perspective Study: Clinical Evaluation of the Persona MC With Preservation or Sacrifice of the PCL
Primary endpoint
-Evaluation of the survival of the implant after 5 years of follow-up
Secondary endpoints
<ul>- 0 views
- 19 Feb, 2024

PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC (PROPHET)
Researchers will use ctDNA dynamics to guide the cycles of induction treatment to see if some patients can avoid excessive cycles of treatment.--UATul>
- 0 views
- 19 May, 2025
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
The trial will be divided into two parts:
PART A:
the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies
PART B:
the second part will include 3 expansion cohorts of …
- 0 views
- 19 Feb, 2024
VARA (Virtual and Augmented Reality Applications in Rehabilitation): Motor Rehabilitation Protocol With GRAIL for Patients Affected by Hemiparesis
- 0 views
- 19 Feb, 2024
A Study to Evaluate the Safety Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers
Secondary objectives:
To characterize pharmacokinetics (PK) of single dose AHCQ in healthy individuals.
- 0 views
- 19 Feb, 2024
Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age
Participants will be categorized based on point-of-care hemoglobin A1c (HbA1c) and periodontal disease (PD) staging into 9 subgroups. The key objectives of the study are:
<ul>- 0 views
- 14 May, 2025
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Part 2: Participants aged 12 < 18 will receive;
<ul>- 0 views
- 19 Feb, 2024
A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.
ul>
Participants will be provided with a diary to solicit reporting of injection site reactions and systemic reactions, unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest AESIs).
- 0 views
- 08 May, 2025
Mobility Protocol Adapted for Advanced Visually Impaired Subjects
People Retinitis Pigmentosa therefore encounter a large number of difficulties in daily life, specifically for:
<ul>This study aims to assess the difficulties in the daily life of subjects with …
- 0 views
- 19 Feb, 2024
Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE) (IMPACT-INSPIRE)
To demonstrate that it is feasible to standardize investigations and endpoints in this proof-of-concept study.
<ul>- 0 views
- 07 May, 2025